(28 Total References)
Designer Drugs For HIV (October 2006)
Dr. Antonin Holy of the Institute of Organic Chemistry and Biochemistry in Prague, Czech Republic, writing in the journal Antiviral Research, reviews the work of his group and others on the modification of NRTI-like drugs, opening their closed ring structures, adding on chemical groups to alter their electric charge and increase their ability to enter cells, and so on.
One international grantee, Dr. Antonin Holy, Senior Research Scientist at the Institute of Organic Chemistry and Biochemistry in Prague, will modify two compounds he discovered, both FDA-approved therapies, to create new formulations that fight resistant virus."Dr.Holy's research may extend the treatment options of patients who have become resistant to current anti-HIV therapies," Dr. Laurence said.
Czech Republic: Europe's New Biotech Corridor at BIO 2005 | Today's Stem Cell Research
Dr. Antonin Holy, whose work in the development of new treatments for the suppression of AIDS (HIV) and hepatitis at the Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic resulted in 2001 and 2002 U.S. Food and Drug Administration approval of Viread, a treatment for AIDS, and Hepsera, a B-hepatitis drug.Both were produced by Gilead Sciences and based on a compound discovered in Dr. Holy's Prague laboratory.
NJBiz.com - New Jersey Business online media newspaper news ebusiness research journal NJBiz
research effort between Dr. Antonin Holy, Institute for Organic Chemistryand Biochemistry, Academy of Sciences of the Czech Republic (IOCB) in
Gilead Sciences And The Institute Of Organic Chemistry And
Donation by Gilead Honors Leadership of Dr. Antonin Holy in Antiviral Drug Discovery and Development
Foster City, CA & Prague, Czech Republic - Gilead Sciences, Inc.
announced a donation to The Institute of Organic Chemistry and Biochemistry at the Academy of Sciences of the Czech Republic
(IOCB) for the establishment of a Gilead Sciences Research Centre
will provide a $1.1 million annual donation to IOCB
for an initial five-year term to fund the Centre's operations and ongoing research activities. IOCB
will use the donations to establish and support the Gilead Sciences Research Centre
, which will consist of selected research groups led by the scientists at IOCB
.In addition, Gilead
will establish the Gilead Distinguished Chair in Medicinal Chemistry.Dr. Antonin Holy, IOCB, will be the first to hold the position of Distinguished Chair and will continue to lead research efforts in nucleoside and nucleotide drug discovery.
The operation of the Research Centre will be governed by a Steering Committee and monitored by an Advisory Board.
In 1991 and 1992, Gilead
entered into license agreements with IOCB
and the Rega Institute for Medical Research
, Katholic University
in Leuven, Belgium that cover a large number of nucleotide analogue compounds and structures.Several of these nucleotide compounds (specifically HPMPC, PMPA and PMEA) discovered through a collaborative research effort between Dr. Antonin Holy
and Dr. Erik DeClercq, Rega Institute
, were developed by Gilead
, resulting in Vistide(R) (cidofovir injection) for the treatment of CMV retinitis in AIDS patients, Viread(R) (tenofovir disoproxil fumarate) for the treatment of HIV infection and Hepsera(R) (adefovir dipivoxil) for the treatment of chronic hepatitis B.
"We are pleased to be able to honor the contribution of Dr. Holy
and the productive collaboration between Gilead and IOCB
over the years through this donation, which will fuel IOCB's leading role in scientific research and drug discovery."
"The scientific pursuit of new targets, new compounds and novel mechanisms for identifying or treating diseases is our most important priority," said Dr. Antonin Holy